Welcome to our dedicated page for Bioxytran SEC filings (Ticker: BIXT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Bioxytran, Inc. (BIXT) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures, including current reports, periodic reports, and insider-related documents filed with the U.S. Securities and Exchange Commission. These filings offer structured insight into Bioxytran’s governance, risk factors, and progress as a clinical-stage biotechnology company focused on antiviral therapies and oxygen transport technologies.
For Bioxytran, Form 8-K current reports are particularly relevant, as they disclose material events such as changes in directors and officers, updates to corporate governance, and significant business developments. Recent 8-K filings describe the resignation of a director who chaired the Audit Committee and recommended enhancements to oversight, internal controls, and approval processes, as well as the termination of an officer whose dismissal is being contested in connection with severance considerations. The company also notes that it engaged an independent third-party financial expert to review its oversight and internal control framework.
Investors can use Bioxytran’s 10-K annual reports and 10-Q quarterly reports (when filed) to review detailed descriptions of its clinical-stage programs, including ProLectin-M, PHM23, BXT-25, and the Universal Oxygen Carrier project, along with risk disclosures, research and development expenses, and information about collaborations and joint ventures such as the partnership with the Heme Foundation.
On Stock Titan, Bioxytran filings are supplemented by AI-powered summaries that explain the key points of lengthy documents, highlight important sections, and help clarify technical language. Real-time updates from the SEC’s EDGAR system ensure that new 8-K, 10-Q, 10-K, and other forms appear promptly. Users can also review Form 4 insider transaction reports when available, to see how officers, directors, and significant shareholders are trading BIXT stock.
Whether you are reviewing Bioxytran’s governance changes, tracking the evolution of its clinical programs, or examining insider activity, the SEC filings page provides a centralized view of the company’s regulatory record with tools that make complex filings easier to interpret.
Bioxytran, Inc. (BIXT) reported insider purchases by a company director. On 08/12/2025, the director acquired 10,417 preferred shares at a price of $0.485 per share. On 11/14/2025, the same director acquired an additional 38,588 preferred shares at a price of $0.35 per share. Following these transactions, the director beneficially owned 379,177 preferred shares, held in direct ownership.
Bioxytran, Inc. (BIXT) reported an insider equity transaction by a director on a Form 4. On 11/14/2025, the director acquired 38,588 preferred shares at a price of $0.35 per share. Following this transaction, the director beneficially owned 372,580 shares, held as a direct ownership position. The filing was made by a single reporting person in the capacity of director, and no derivative securities transactions were reported.
Bioxytran, Inc. insider David Platt, who serves as CEO, director, and a 10% owner, reported changes in his indirect holdings of preferred stock on a Form 4/A. On 10/24/2024, 14,085,410 preferred shares held through NDPD Pharma were returned to treasury and cancelled. On the same date, 11,433,448 preferred shares were issued as payment for the sale of NDPD to Bioxytran, leaving Platt with 20,038,903 preferred shares beneficially owned indirectly through NDPD Pharma. The filing consolidates NDPD Pharma’s Bioxytran holdings under Platt’s indirect ownership.
Bioxytran, Inc. (BIXT) reported an amended insider transaction for Chief Commercial Officer and director Michael Sheikh. On 10/25/2024, he acquired 6,614,720 common shares of Bioxytran at a price of $0.545 per share, reported as an acquisition. After this transaction, he beneficially owned 8,214,720 shares, held directly. The filing explains that these shares were issued as payment for the sale of NDPD Pharma to Bioxytran, meaning the consideration for that business sale was paid in Bioxytran stock rather than cash.
Bioxytran, Inc. insider Ola Soderquist, who serves as CFO and is a 10% owner, reported multiple equity transactions dated 10/25/2024. He acquired 10,069,396 shares of preferred stock at $0.545 per share, bringing his beneficial ownership in that class to 13,976,456 preferred shares. He also acquired an additional 100,000 preferred shares at $0.005 per share, after which he held 13,876,456 preferred shares. In addition, he acquired 500,000 shares of common stock at $0.001 per share and held 500,000 common shares directly after the transaction. The filing states that some shares were issued as payment for the sale of NDPD Pharma to Bioxytran and that there was a 1:5 exchange of preferred stock into common stock.
Bioxytran, Inc. filed its Q3 2025 report, highlighting continued losses and tight liquidity. The company posted a Q3 net loss of $282,726 and a nine‑month net loss of $1,600,922. Cash was $14,499 at September 30, 2025, with a negative working capital of $3,046,438, and management disclosed “substantial doubt” about the ability to continue as a going concern.
Total assets were $156,294, including intangibles of $141,795. Current liabilities were $3,060,937, driven by accounts payable, an embedded‑feature derivative liability of $419,206, and convertible notes payable and accrued interest totaling $1,046,433. The convertible note is convertible at the lesser of fixed thresholds with a price‑adjustment feature, implying potential issuance of approximately 15.1 million shares based on the stated conversion terms.
Common shares outstanding were 88,992,243 and preferred shares outstanding were 43,429,639 as of September 30, 2025. Warrants outstanding totaled 1,292,030. The filing also notes increased R&D spending of $452,000 for the nine months, reflecting ongoing development efforts.